A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2009
12/02/2009	EP2124890A2 Use of sucrose to suppress mannitol-induced protein aggregation
12/02/2009	EP2124889A2 Protein formulations containing sorbitol
12/02/2009	EP1716169B1 Ornithobacterium rhinotracheale subunit vaccines
12/02/2009	EP1684801B1 Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
12/02/2009	EP1664100B1 Lawsonia intracellularis subunit vaccine
12/02/2009	EP1534670B1 Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs
12/02/2009	EP1248804B2 Recombinant antibodies to human interleukin-1 beta
12/02/2009	EP1180041B2 Vaccine against isa virus
12/02/2009	CN101595219A Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
12/02/2009	CN101595213A Cancerous disease modifying antibodies
12/02/2009	CN101595131A Methods of reducing phosphate absorption
12/02/2009	CN101595130A Compositions and methods for the diagnosis and treatment of tumor
12/02/2009	CN101595127A Protein composition for inducing an immune response in a vertebrate comprising a plurality of protein variants covering the heterogeneity of a single antigen, ama1
12/02/2009	CN101595126A Use of a first house dust mite group 2 allergen for treating allergy to a second house dust mite group 2 allergen
12/02/2009	CN101594883A Diagnosis and treatment of cancer using anti-EREG antibody
12/02/2009	CN101594882A Interferon alpha-induced pharmacodynamic markers
12/02/2009	CN101594881A Precipitated/inactivated influenza vaccine and method for production thereof
12/02/2009	CN101594880A Novel method for treating H.pylori infections
12/02/2009	CN101594872A Prostaglandin E2 (PGE2) as an adjuvant in monoclonal antibody generation
12/02/2009	CN101591666A Preparation for pCN-SSISG of dual-promoter bivalent anti-caries DNA vaccine
12/02/2009	CN101591665A Slpa as a tool for recombinant protein and enzyme technology
12/02/2009	CN101591647A Viral particles with exogenous internal epitopes
12/02/2009	CN101591646A Dendritic cell vaccine for treating human cervical carcinoma
12/02/2009	CN101591396A Anti-erbB2 human antibody MIL-5 and application thereof
12/02/2009	CN101591395A Human single chain antibody and application of antitumor vascular endothelium marker molecule 8-cell outer region
12/02/2009	CN101591393A Hydrophobia-tetanus double titer human immunoglobulin, method for preparing same and application thereof in pharmacy
12/02/2009	CN101591389A Varicella-zoster human immunoglobulin, method for preparing same and application thereof in pharmacy
12/02/2009	CN101591379A Constructed anti-HIV vaccine based on amino acid mutation of EIAV attenuated live vaccine
12/02/2009	CN101590227A Vaccine product with respectively packaged freeze-dried vaccine and dilute solution thereof and method for preparing dilute solution
12/02/2009	CN101590226A ACY W135 group meningococcal polysaccharide type-b haemophilus influenzae conjugate vaccine
12/02/2009	CN101590225A Vaccine combining DTP (diphtheria,tetanus and pertussis) and A plus C group meningococcus-b type haemophilus influenzae
12/02/2009	CN101590224A High-efficiency 14-valent pneumococcal conjugate vaccine
12/02/2009	CN100564527C A-type kreotoxin receptor combination region Hc, coding protein and application thereof
12/02/2009	CN100563709C Novel targeted tissue factor antibody as anticoagulants
12/02/2009	CN100563708C Method for preparing gram-negative pathogenic bacteria inactivated vaccine having cross-protection power
12/02/2009	CN100563707C Activation and inhibition of the immune system
12/01/2009	US7626013 HIV-1 DNA fragments that hybridize to genomic HIV-1DNA
12/01/2009	US7626012 Nucleic acids encoding monoclonal antibody or an antigen-binding portion thereof that specifically binds to and activates human CD40; Gene therapy; nucleic acid coding immunoglobulins; anticancer agents
12/01/2009	US7626002 Cytokine zalpha11 ligand antibodies
12/01/2009	US7626000 Membrane proteins
12/01/2009	US7625917 S-o-(phenylaminocarbonyl)phenyl-substituted, especially with a quaternary onium group; enhanced antiviral activity and better reactivity with zinc finger moieties, particularly, the zinc finger on HIV-1's NCp7 nucleocapsid protein
12/01/2009	US7625879 Phosphohalohydrins, process for the production thereof and use thereof
12/01/2009	US7625872 a branch-point nucleoside to which three core nucleic acid moieties are covalently coupled; therapy for cancer and Th2-type immune response (e.g., an allergy or allergy-induced asthma) by increasing the secretion of interferon-gamma
12/01/2009	US7625868 Methods and compositions for inhibiting angiogenesis
12/01/2009	US7625860 Administering a combination of a cytotoxic agent and a fibroblastic growth factor antagonist, wherein the FGF antagonist enhances the efficacy of the cytotoxic agent
12/01/2009	US7625859 HER-2 binding antagonists
12/01/2009	US7625736 Includes a hapten or an antigen covalently linked to a carrier; not reversible at physiological pH, and that do not require reduction with boron-hydride
12/01/2009	US7625573 Immunology active materials; anticancer agents, infections, autoimmune diseases, parasiticides; lipid bilayer with antitumor agent
12/01/2009	US7625572 Immunogens; shuttle vectors; do not display antibiotic resistance, and do not exhibit horizontal transfer to gram-negative bacteria; vaccines
12/01/2009	US7625571 Transformed bacteria producing CS6 antigens as vaccines
12/01/2009	US7625570 Methods for purifying adeno-associated virus
12/01/2009	US7625569 Vaccines; fusion protein; induce immunology response
12/01/2009	US7625567 Induction of immune responses to isoaspartyl-modified antigens
12/01/2009	US7625566 Monoclonal antibody for use as tool in prevention and treatment of viral disease; viricides
12/01/2009	US7625565 Antiviral compositions comprising lysine-rich histone fractions prepared by pepsin treatment of thymic cell nuclei
12/01/2009	US7625564 Immunoglobulins; immunogens
12/01/2009	US7625563 Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
12/01/2009	US7625562 Generation of cartilage using magnetizable particles
12/01/2009	US7625561 Diabody which specifically binds Streptococcus surface antigen I/II and methods of use thereof
12/01/2009	US7625560 Humanized antibodies that recognize beta amyloid peptide
12/01/2009	US7625559 Antibodies against Clostridium difficile toxins and uses thereof
12/01/2009	US7625558 Anticancer agents; administering nucleic acid which dimerizes with protein
12/01/2009	US7625557 Transimmunization methods incorporating skin immunologic challenges are described for selectively suppressing immune response of recipients of transplanted tissue or cells or monitoring induced anti-cancer immunity
12/01/2009	US7625556 E. coli bacteriophage and uses thereof
12/01/2009	CA2407210C Liposome drug delivery
12/01/2009	CA2305533C Multilamellar coalescence vesicles (mlcv) containing biologically active compounds
12/01/2009	CA2298956C Genetically engineered cell culture adapted infectious bursal diseases virus (ibdv) mutants
12/01/2009	CA2208503C Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
12/01/2009	CA2154163C Ligand antagonists for treatment of breast cancer
11/2009
11/26/2009	WO2009143524A2 Nanoemulsion vaccines
11/26/2009	WO2009143483A2 PsrP IS A PROTECTIVE ANTIGEN AGAINST PNEUMOCOCCAL INFECTION
11/26/2009	WO2009143472A2 Method of generating single vl domain antibodies in transgenic animals
11/26/2009	WO2009143470A1 Method for treating disease characterized by plaque
11/26/2009	WO2009143465A1 Method of imaging abnormal deposits or plaques
11/26/2009	WO2009143457A2 Vaccine composition containing synthetic adjuvant
11/26/2009	WO2009143453A2 Methods and compositions for reducing lung inflammation in an animal
11/26/2009	WO2009143413A1 Synergistic immunogenic fusion protein-polysaccharide conjugate
11/26/2009	WO2009143411A2 Methods, compositions and apparatus for facilitating regeneration
11/26/2009	WO2009143308A2 Protein self-producing artificial cell
11/26/2009	WO2009143280A2 Nanolipoprotein particles and related compositions, methods and systems
11/26/2009	WO2009143168A2 Vaccine assays
11/26/2009	WO2009143085A1 Compositions comprising prfa*mutant listeria and methods of use thereof
11/26/2009	WO2009143006A1 Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
11/26/2009	WO2009142988A2 Chitin micro-particles as an adjuvant
11/26/2009	WO2009142810A2 Methods for treating or preventing colorectal cancer
11/26/2009	WO2009142738A2 Compositions and methods for diagnosing and treating cancer
11/26/2009	WO2009142460A2 Antibody-peptide fused synergibody
11/26/2009	WO2009142186A1 Cytotoxic composition
11/26/2009	WO2009142086A1 Vaccine composition for mycoplasma infection
11/26/2009	WO2009141736A2 Inhibition of emmprin to treat multiple sclerosis
11/26/2009	WO2009141729A2 Anti-tumoral cells
11/26/2009	WO2009141455A1 Immunogenic polypeptides that mimic the surface polysaccharide o-antigen from serotype 2a shigella flexneri, method for obtaining the same, and their use in vaccine and diagnostic compositions
11/26/2009	WO2009141434A1 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant
11/26/2009	WO2009141388A1 Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
11/26/2009	WO2009141335A1 An adapter molecule for the delivery of adenovirus vectors
11/26/2009	WO2009141239A1 A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
11/26/2009	WO2009140755A1 An anti-cancer cytotoxic monoclonal antibody
11/26/2009	WO2009140754A1 An anti-cancer cytotoxic monoclonal antibody
11/26/2009	WO2009125231A3 Anti-atheroma vaccine
11/26/2009	WO2009118204A3 Medicament, compositions, and substances for treating and identifying adenocarcinoma of the lung

1 ... 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 ... 1823